Drug reference

Ivermectin

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1361, 1362

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Papulopustular rosacea ▶TO THE SKIN ▶Adult: Apply daily for up to 4 months, the treatment course may be repeated; discontinue if no improvement after 3 months

PDF page 1361

National Funding Access Decisions

Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (December 2015) that ivermectin (Soolantra ®) is accepted for restricted use within NHS Scotland for the treatment of moderate-to-severe inﬂammatory lesions of rosacea (papulopustular) where a topical treatment is considered appropriate. All Wales Medicines Strategy Group (AWMSG) decisions The All Wales Medicines Strategy Group has advised (April 2016) that ivermectin (Soolantra ®) is recommended as an option for use within NHS Wales for the topical treatment of inﬂammatory lesions of rosacea (papulopustular) in adult patients.

PDF page 1362

Safety

Interactions

→Appendix 1: ivermectin

PDF page 1361

Side Effects

▶Common or very common Skin reactions

PDF page 1361

Pregnancy

Manufacturer advises avoid—limited information but toxicity following oral use in animal studies.

PDF page 1361

Breast Feeding

Manufacturer advises avoid—limited information but present in milk following oral use.

PDF page 1361

Hepatic Impairment

Manufacturer advises caution in severe impairment (no information available).

PDF page 1361

Dose and formulations

Directions For Administration

Manufacturer advises apply thinly to the face only, avoiding contact with eyes, lips and mucosa.

PDF page 1361

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Cream CAUTIONARY AND ADVISORY LABELS 28 EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and Skin stearyl alcohol), disodium edetate, isopropyl palmitate, propylene glycol ▶Soolantra (Galderma (UK) Ltd) Ivermectin 10 mg per 1 gram Soolantra 10mg/g cream | 30 gram P £18.29 DT = £18.29 SYMPATHOMIMETICS › ALPHA2-ADRENOCEPTOR AGONISTS

PDF page 1362

Clinical care

Patient And Carer Advice

Wash hands immediately after use.

PDF page 1361

Dose text by age group

Adult

Apply daily for up to 4 months, the treatment

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1361

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Ivermectin

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1361, 1362

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Papulopustular rosacea ▶TO THE SKIN ▶Adult: Apply daily for up to 4 months, the treatment course may be repeated; discontinue if no improvement after 3 months

PDF page 1361

National Funding Access Decisions

PDF page 1362

Safety

Interactions

→Appendix 1: ivermectin

PDF page 1361

Side Effects

▶Common or very common Skin reactions

PDF page 1361

Pregnancy

Manufacturer advises avoid—limited information but toxicity following oral use in animal studies.

PDF page 1361

Breast Feeding

Manufacturer advises avoid—limited information but present in milk following oral use.

PDF page 1361

Hepatic Impairment

Manufacturer advises caution in severe impairment (no information available).

PDF page 1361

Dose and formulations

Directions For Administration

Manufacturer advises apply thinly to the face only, avoiding contact with eyes, lips and mucosa.

PDF page 1361

Medicinal Forms

PDF page 1362

Clinical care

Patient And Carer Advice

Wash hands immediately after use.

PDF page 1361

Dose text by age group

Adult

Apply daily for up to 4 months, the treatment

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1361

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.